HomeGNMLF • OTCMKTS
add
Genomma Lab Internacional SAB de CV
Previous close
$1.00
Year range
$0.93 - $1.27
Market cap
17.26B MXN
Avg Volume
7.00
P/E ratio
-
Dividend yield
-
Primary exchange
BMV
Market news
Financials
Income Statement
Revenue
Net income
| (MXN) | Dec 2025info | Y/Y change |
|---|---|---|
Revenue | 4.02B | -13.90% |
Operating expense | 1.65B | -17.47% |
Net income | 319.64M | -25.20% |
Net profit margin | 7.96 | -13.10% |
Earnings per share | 0.32 | -31.91% |
EBITDA | 895.41M | -15.95% |
Effective tax rate | 43.73% | — |
Balance Sheet
Total assets
Total liabilities
| (MXN) | Dec 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 3.07B | 35.04% |
Total assets | 23.83B | 3.55% |
Total liabilities | 12.72B | 4.86% |
Total equity | 11.11B | — |
Shares outstanding | 976.73M | — |
Price to book | 0.09 | — |
Return on assets | 8.44% | — |
Return on capital | 10.79% | — |
Cash Flow
Net change in cash
| (MXN) | Dec 2025info | Y/Y change |
|---|---|---|
Net income | 319.64M | -25.20% |
Cash from operations | 1.26B | -2.26% |
Cash from investing | -322.91M | -950.57% |
Cash from financing | -192.22M | 68.95% |
Net change in cash | 677.61M | 2.86% |
Free cash flow | 809.57M | 457.17% |
About
Genomma Lab Internacional or simply Genomma Lab is a Mexican company, founded in 1996, dedicated to the commercialization of OTC medications and dermocosmetic products. It is part of the Índice de Precios y Cotizaciones, the main stock index of the Mexican Stock Exchange. It is one of the leading pharmaceutical companies in the country.
Genomma Lab Internacional, led by its owner Rodrigo Alonso Herrera Aspra, recorded net sales of 9,799.7 million Mexican pesos, equivalent to 756.0 million USD in 2012, achieving a 21.6% growth compared to 2011. Currently, Genomma Lab operates in 15 countries outside Mexico and has achieved success by replicating its business model. Wikipedia
Founded
1996
Website
Employees
1,465
